Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
about
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategiesRecent advances in understanding myelofibrosis and essential thrombocythemiaGenomic landscape of megakaryopoiesis and platelet function defectsPathophysiological Significance of Store-Operated Calcium Entry in Megakaryocyte Function: Opening New Paths for Understanding the Role of Calcium in ThrombopoiesisMomelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.Safety considerations when treating myelofibrosis.The Calreticulin gene and myeloproliferative neoplasms.The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin.Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.Aberrant let7a/HMGA2 signaling activity with unique clinical phenotype in JAK2-mutated myeloproliferative neoplasmsIncreased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic TransformationExpression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.JAK2 inhibitors for myeloproliferative neoplasms: what is next?Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis.Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.Primary myelofibrosis and its targeted therapy.Ruxolitinib dose management as a key to long-term treatment success.Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A ReviewRole of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary MyelofibrosisThe role of the extracellular matrix in primary myelofibrosis.Myeloproliferative neoplasm stem cells.Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery.Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Epigenetics in Myeloproliferative Neoplasms.Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and SplenomegalyGenetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinibmiR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6.Calreticulin in Essential Thrombocythemia: StressINg OUT the Megakaryocyte Nucleus
P2860
Q26744113-A1BF6BD9-3D7F-44C0-B0A7-6D45D7C59102Q26748543-0825F926-3ACA-4355-A434-34212DDD8F9AQ26770869-8604C6B6-4909-4779-BF48-C095533D76B2Q28069839-5787EF88-23CE-45A9-BD28-BCDFAF6162B1Q30244032-6283324D-F7D0-47E9-93A3-C82A74DDA383Q33432285-58FDF1E7-E47E-4FD5-BDD0-8A875751CD7AQ33433481-FEB94462-B2D6-4A5A-9A95-24368B6EF58AQ33440994-C7B6550E-50ED-4CFC-A546-DE2860BAD38AQ33443580-D8624DBA-14F9-40B9-A44D-8BF051D4D1ADQ33573793-ED44319B-1F4A-4D41-97D7-4C92005F8EE3Q33779135-5CDC694B-1992-46B7-AD66-131FEB41D876Q36853951-EB77BA6A-3FA6-4C99-8836-125DE6E6BE40Q37397491-178EB8B2-CFB0-4D35-9125-59618D897415Q37555785-32349B40-A6D8-4A93-B005-9687E64C6E1EQ37638779-938125B2-2AF1-450E-8D45-AA609E9CED7AQ37679175-8D2490DB-33C3-43E6-BC98-682CC9136702Q37740931-A044FF50-62BA-4794-9100-7B3B53756348Q38660742-62133257-6734-4518-A9A0-78209025B993Q38684435-A6595D0F-6D8B-48E4-B57E-678FA2CF7B04Q38717569-C538A0FD-FB2F-4EF9-9F2C-A095746AAE68Q38771057-E074EE98-B118-47F7-AE73-6F1721CE5F2DQ38798560-C4B18558-42BD-4671-8948-80FC62874D1DQ38844669-D43459CF-EAF8-40AD-88A3-68DBC6F6EFE4Q38931426-77F9BCD4-C096-4E12-BA11-9DF2EBCA55DEQ38938939-2300DF1A-DB7A-4664-80EA-C6EFA815BEA7Q38978004-CD60E92B-828A-44CA-BB2E-CD629198BA89Q38984558-A174AF85-41B1-4BD2-8D3B-E1569CC96387Q39015118-49CE300B-0119-4C2C-86E8-9C9DE154EE1AQ39117766-3CBE6347-025B-4797-A278-95B1304B1DCFQ39118859-B1D2714F-E13C-4E37-902F-9380EF1CFD89Q39306368-7068FF51-2992-4ABF-87BA-4B384C1D1016Q39321106-0ABD761F-0233-43EA-AE34-0F4E2F621152Q39414554-28F4FFFB-D78F-4201-B20D-B86161531224Q39457113-B76282F5-FE44-4050-957D-73714F2D6A58Q39986585-86F6DC1B-BDF8-49E8-AF17-4158B15C7F32Q40564541-F138EB93-6811-4D05-B8AA-5029B6CBE86AQ41684028-60C91039-5B22-4B50-AC7F-8EBF5A5F1A9FQ41955541-A7448F0F-0265-4FC0-92DA-1F2CA34046CCQ42089573-E91389EE-930B-463C-B258-D3803993FD12Q42253829-6E52FB5A-841D-4AF0-9AFE-D22D1261CABB
P2860
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Thrombopoietin receptor activa ...... sociated calreticulin mutants.
@en
type
label
Thrombopoietin receptor activa ...... sociated calreticulin mutants.
@en
prefLabel
Thrombopoietin receptor activa ...... sociated calreticulin mutants.
@en
P2093
P50
P1433
P1476
Thrombopoietin receptor activa ...... ssociated calreticulin mutants
@en
P2093
Caroline Marty
Christian Pecquet
Gaëlle Vertenoeil
Harini Nivarthi
Ilyas Chachoua
Jean-Philippe Defour
Mira El-Khoury
Pierre J Courtoy
P304
P356
10.1182/BLOOD-2015-11-681932
P407
P577
2015-12-14T00:00:00Z